Artivion (AORT) Set to Post Earnings on Thursday

Artivion (NYSE:AORT) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Artivion to post earnings of ($0.0612) per share and revenue of $120.97 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The company had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, analysts expect Artivion to post $0.45 EPS for the current fiscal year and $0.77 EPS for the next fiscal year.

Artivion Trading Up 0.0%

Shares of Artivion stock opened at $22.95 on Thursday. The firm has a market capitalization of $1.12 billion, a PE ratio of -327.80 and a beta of 1.23. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm’s 50 day moving average is $24.09 and its 200 day moving average is $29.66.

Analysts Set New Price Targets

AORT has been the topic of a number of research reports. Needham & Company LLC reissued a “buy” rating and set a $44.00 target price on shares of Artivion in a report on Monday, July 20th. Weiss Ratings lowered shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Canaccord Genuity Group increased their price objective on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Jefferies Financial Group began coverage on Artivion in a research report on Tuesday, October 20th. They set a “buy” rating and a $31.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.86.

Insider Transactions at Artivion

In other news, SVP Jean Holloway sold 977 shares of Artivion stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares in the company, valued at $5,245,521.82. This trade represents a 0.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO James Mackin sold 70,000 shares of Artivion stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the transaction, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 90,460 shares of company stock worth $2,557,366 in the last quarter. Company insiders own 6.30% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.